search
IBRX
Trends
- 1ImmunityBio slides despite Anktiva FDA win as investors wait▼IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk
ImmunityBio (IBRX) shares are heading for a weekly decline even after a positive FDA development for Anktiva, the company's cancer immunotherapy. Retail investors remain cautious, with attention focused on remarks expected from founder Patrick Soon-Shiong regarding a trial. Investors appear unconvinced the regulatory win is enough to offset concerns about the company's clinical pipeline and spending.
- 2ImmunityBio Stock Slides as Retail Investors Call It a Bargain▼IBRX Stock Under Pressure: Retail Sees 'Ridiculously Cheap' Bargain As Founder Touts Sister Firm NantIQ's Aetna Work
ImmunityBio (IBRX) shares are under pressure, but retail traders argue the biotech is 'ridiculously cheap' at current levels. Attention is also on founder Patrick Soon-Shiong, who has been promoting work by sister company NantIQ with insurer Aetna, adding to debate over the firm's prospects.